Overview
Velocity Clinical Research operates the world’s largest network of fully integrated clinical research sites, with 70+ sites and 200+ investigators, collaborating with pharmaceutical and biotechnology companies to study new drugs, medical devices, diagnostics, and combination products. Its unified site solutions connect the right patients, investigators, and research staff across the U.S. and Europe, enabling efficient trial execution. A technology hub in India develops systems that leverage site, patient, and historical performance data to improve operations. The company’s approach centers on delivering high-quality data, excellent patient care, and greater efficiency for clinical trials at any scale. Its differentiators include a broad, integrated site network, global reach, and a focus on data-driven processes to speed research while maintaining quality.
Work here?Claim your company
Simplify's take
What believers are saying
- Justin Starzyk became CEO on September 18, 2026, bringing scaling discipline from multisite healthcare services.
- Velocity and Stitch expanded their partnership on September 10, 2026, across all U.S. and Europe sites.
- Velocity's August 27, 2026 data milestone speeds database lock and strengthens sponsor renewal leverage.
What critics are saying
- Melissa Cuevas filed a California TCPA class action in February 2026, risking damages and discovery.
- GHO bought Velocity in 2021; Justin Starzyk now faces exit-pressure for margin expansion.
- One lost anchor sponsor would idle 70+ sites fast, crushing utilization and staffing economics.
What makes Velocity Clinical Research unique
- GHO-backed, fully owned network spans 70+ sites across four countries, centralized under one operator.
- September 2026 Stitch rollout covers all sites after a pilot lifting screening show-rates nine points.
- August 2026 centralized EDC enters 97% of data within 24 hours, with 99% accuracy.
Help us improve and share your feedback! Did you find this helpful?